Enzon Inc. of Piscataway, N.J., announced Tuesday that it hasbeen issued U.S. Patent No. 5,234,903 for its red blood cellsubstitute, PEG-hemoglobin, which is currently underdevelopment.

The patent is directed to human and non-human hemoglobinthat has been chemically modified using Enzon's(NASDAQ:ENZN) proprietary technology, Pegnology. Enzon'sPeg-hemoglobin is based on bovine hemoglobin, which maydecrease the risk of viral transmission during transfusion andeliminate the need for blood typing and matching.

(c) 1997 American Health Consultants. All rights reserved.